Full Press Release Details
Immutep Announces Second Japanese Patent Grant for LAG-3 Antagonist Antibody LAG525.
IMMP
Immutep Announces Second Japanese Patent Grant for LAG-3 Antagonist Antibody LAG525
Key Takeaway: Immutep Announces Second Japanese Patent Grant for LAG-3 Antagonist Antibody LAG525
Price reaction · baseline $2.72 (2022-03-17 close) · hit after-hours · 2 other IMMP headline(s) in the window, move may be shared
day 0 close
+14%
day 1
+17.3%
day 3 · peak
+25.7%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+76%
120-day peak, hindsight
Typical move
5.4%
average across 13 past catalysts
Lead asset
eftilagimod alfa
Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)